Bryce Cleveland, CEO of Scalpa, Inc., pleaded guilty to three charges involving unapproved skincare products and mail fraud. The charges include introducing adulterated devices and unapproved drugs into interstate commerce, as well as mail fraud. Cleveland, 42, was apprehended in Colombia in 2025 and returned to the U.S. after an indictment in July 2024. Between 2018 and 2020, he orchestrated a scheme to market unapproved devices like the ScalpaJECT Hyaluronic Acid pen and the unapproved drug Scalpatox, falsely claiming they were not FDA-regulated. Injectable products like Scalpatox pose significant public health risks due to potential systemic harm. The FDA warned of adverse events linked to unapproved botulinum toxin products. Cleveland faces a four-to-eight-year prison term, restitution, and a $800,000 forfeiture. The FDA Office of Criminal Investigations, U.S. Postal Inspection Service, and DOJ collaborated on the case. Prosecutors include Assistant U.S. Attorneys Corey Hall and Randy Ramseyer, and Trial Attorney Taylor Broadbent.
Source: U.S. Department of Justice (DOJ).
Materials reproduced from https://www.justice.gov/.
No endorsement by the DOJ is implied.
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.